Pregabaline Lyrica 300mg
Pregabaline Lyrica 300mg is a treatment that can be initiated at a dose of 150 mg per day administered in two or three doses. Depending on the patient’s response and tolerance, the dose may be increased to 300 mg daily after 1 week. The maximum dose of 600 mg per day can be reached after an additional week.
The dosage varies from 150 to 600 mg per day, in two or three doses. The need for continued treatment should be reassessed regularly.
Pregabalin treatment can be initiated at a dose of 150 mg per day. Depending on the patient’s response and tolerance, the dose may be increased to 300 mg daily after 1 week. After a further week, the dose can be increased to 450 mg per day. The maximum dose of 600 mg per day can be reached after an additional week.
In accordance with current clinical practice, if pregabalin treatment must be discontinued, it is recommended to do so gradually over a minimum period of 1 week regardless of the indication (see sections 4.4 and 4. unwanted).
Creatinine Clearance (CLcr) (ml/min) Pregabalin Total Daily Dose* Dosing Regimen Starting Dose (mg/day) Maximum Dose (mg/day) ≥ 60 150 600 BID or TID ≥ 30 – < 60 75 300 BID or TID ≥ 15 – < 30 25 – 50 150 Once daily or BID < 15 25 75 Once daily Additional dose after hemodialysis (mg) 25 100 Single dose+
The safety and effectiveness of Lyrica in children under 12 and in adolescents (12-17 years) have not been established. Currently available data are described under Adverse effects, Pharmacodynamic properties and Pharmacokinetic properties, but no recommendation on a posology can be given.
Due to decreased renal function, a reduction in pregabalin dose may be required in elderly patients (see section 5.2). During marketing, the most frequently reported adverse effects in the event of overdose with pregabalin were: drowsiness, confusional state, agitation and nervousness. Seizures have also been reported.
Precautions For Use
Hypersensitivity to the active substance or to any of the excipients mentioned under List of excipients.